Methocarbamol and Telmisartan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methocarbamol (methocarbamol) and Telmisartan (telmisartan). Common drug interactions include weight decreased among females and diabetes mellitus inadequate control among males.

The phase IV clinical study analyzes what interactions people have when they take Methocarbamol and Telmisartan. It is created by eHealthMe based on reports of 37 people who take the same drugs from the FDA, and is updated regularly.

What is Methocarbamol?

Methocarbamol has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 17,766 Methocarbamol users. Check the latest studies of Methocarbamol.

What is Telmisartan?

Telmisartan has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 9,163 Telmisartan users. Check the latest studies of Telmisartan.



On Jul, 06, 2026

37 people who take Methocarbamol and Telmisartan together, and have interactions are studied.

Methocarbamol and Telmisartan drug interactions.

What are the common drug interactions of Methocarbamol and Telmisartan, by gender? *:

female:

  1. Weight decreased
  2. Weight increased
  3. Sinusitis (inflammation of sinus)
  4. Urinary tract infection
  5. Dizziness
  6. Kidney infection
  7. Nausea (feeling of having an urge to vomit)
  8. Skin infection
  9. Depression
  10. Influenza

male:

  1. Diabetes mellitus inadequate control
  2. Diabetic coma
  3. Abnormal behaviour
  4. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  5. Depression
  6. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  7. Dyspepsia (indigestion)
  8. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
  9. Gout (uric acid crystals building up in the body)
  10. Haemorrhoids (a swollen vein or group of veins in the region of the anus)

What are the common drug interactions of Methocarbamol and Telmisartan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Diabetes mellitus inadequate control
  2. Diabetic coma
  3. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
  4. Pancreatitis (inflammation of pancreas)
  5. Type 2 diabetes mellitus

30-39:

n/a

40-49:

  1. Dizziness
  2. Meniere's disease (a disorder of the inner ear that can affect hearing and balance to a varying degree)
  3. Nausea (feeling of having an urge to vomit)
  4. Influenza
  5. Infusion site swelling
  6. Nasopharyngitis (inflammation of the nasopharynx)
  7. Sinusitis (inflammation of sinus)
  8. Cancer pain
  9. Cataract (clouding of the lens inside the eye)
  10. Depression

50-59:

  1. Depression
  2. Surgery
  3. Agitation (state of anxiety or nervous excitement)
  4. Arthralgia (joint pain)
  5. Bacteraemia (presence of bacteria in the blood)
  6. Blood pressure decreased
  7. Breath sounds
  8. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  9. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  10. Disorientation (disability in which the senses of time, direction, and recognition of people and places)

60+:

  1. Urinary tract infection
  2. Kidney infection
  3. Insomnia (sleeplessness)
  4. Pain of skin
  5. Pruritus (severe itching of the skin)
  6. Psoriasis (immune-mediated disease that affects the skin)
  7. Skin swelling
  8. Surgery
  9. Skin infection
  10. Sinusitis (inflammation of sinus)

What are the existing conditions these people have? *

  1. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 6 people, 16.22%
  2. Immunodeficiency Common Variable: 6 people, 16.22%
  3. Psoriasis (immune-mediated disease that affects the skin): 3 people, 8.11%
  4. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 8.11%
  5. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 3 people, 8.11%
  6. Combined Immunodeficiency: 3 people, 8.11%
  7. Drowsiness: 3 people, 8.11%
  8. Gout (uric acid crystals building up in the body): 2 people, 5.41%
  9. Cataract (clouding of the lens inside the eye): 2 people, 5.41%
  10. Depression: 2 people, 5.41%

* Approximation only. Some reports may have incomplete information.

Do you take Methocarbamol and Telmisartan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Methocarbamol and Telmisartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Methocarbamol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Telmisartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methocarbamol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Telmisartan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on methocarbamol and telmisartan (the active ingredients of Methocarbamol and Telmisartan, respectively), and Methocarbamol and Telmisartan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: